Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990621342> ?p ?o ?g. }
- W2990621342 endingPage "257" @default.
- W2990621342 startingPage "248" @default.
- W2990621342 abstract "IntroductionConsolidation durvalumab after chemoradiation (CRT) is the current standard of care for locally advanced NSCLC. We hypothesized that adding immunotherapy concurrently with CRT (cCRT) would increase efficacy without additive toxicity.MethodsThis phase II study was conducted in two parts. Part 1 (n = 10) involved administration of conventionally fractionated CRT followed by consolidation chemotherapy (atezolizumab [two cycles] and maintenance atezolizumab up to 1 y). Part 2 (n = 30) involved administration of cCRT with atezolizumab followed by the same consolidation and maintenance therapies as in part 1. Programmed cell death ligand-1 staining cutoffs (1% or 50%) using Dako 22C3 immunohistochemistry were correlated with clinical outcomes.ResultsThe overall toxicities for part 1/2 were overall adverse events of grade 3 and above of 80%/80%; immune-related adverse events of grade 3 and above of 30%/20%; and pneumonitis of grade 2 and above of 10%/16%, respectively. In part 1, for preliminary efficacy results, with a median follow-up of 22.5 months, the median progression-free survival was 18.6 months, and the overall survival was 22.8 months. In part 2, with a median follow-up time of 15.1 months, the median progression-free survival was 13.2 months, and the overall survival was not reached. There was no difference in cancer recurrence regardless of programmed cell death ligand-1 status.ConclusionsAtezolizumab with cCRT is safe and feasible and has no added toxicities compared with historical rates." @default.
- W2990621342 created "2019-12-05" @default.
- W2990621342 creator A5002347804 @default.
- W2990621342 creator A5004505157 @default.
- W2990621342 creator A5008692926 @default.
- W2990621342 creator A5008781374 @default.
- W2990621342 creator A5009466654 @default.
- W2990621342 creator A5010884206 @default.
- W2990621342 creator A5022273534 @default.
- W2990621342 creator A5037468064 @default.
- W2990621342 creator A5039160380 @default.
- W2990621342 creator A5040095241 @default.
- W2990621342 creator A5041062966 @default.
- W2990621342 creator A5044755649 @default.
- W2990621342 creator A5048380048 @default.
- W2990621342 creator A5048517627 @default.
- W2990621342 creator A5055965589 @default.
- W2990621342 creator A5057281549 @default.
- W2990621342 creator A5065839430 @default.
- W2990621342 creator A5067755477 @default.
- W2990621342 creator A5070156025 @default.
- W2990621342 creator A5077579849 @default.
- W2990621342 creator A5077763767 @default.
- W2990621342 creator A5078248328 @default.
- W2990621342 creator A5086483620 @default.
- W2990621342 date "2020-02-01" @default.
- W2990621342 modified "2023-10-17" @default.
- W2990621342 title "Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC" @default.
- W2990621342 cites W1968899146 @default.
- W2990621342 cites W2052727153 @default.
- W2990621342 cites W2093883889 @default.
- W2990621342 cites W2128821986 @default.
- W2990621342 cites W2140469315 @default.
- W2990621342 cites W2149089484 @default.
- W2990621342 cites W2152939220 @default.
- W2990621342 cites W2159094759 @default.
- W2990621342 cites W2527905628 @default.
- W2990621342 cites W2709256292 @default.
- W2990621342 cites W2745126191 @default.
- W2990621342 cites W2753065806 @default.
- W2990621342 cites W2756648224 @default.
- W2990621342 cites W2788208686 @default.
- W2990621342 cites W2805354595 @default.
- W2990621342 cites W2891760302 @default.
- W2990621342 cites W2893824814 @default.
- W2990621342 cites W2893960509 @default.
- W2990621342 cites W2909427482 @default.
- W2990621342 cites W2943437728 @default.
- W2990621342 cites W2946562078 @default.
- W2990621342 cites W2946881487 @default.
- W2990621342 cites W2947917747 @default.
- W2990621342 doi "https://doi.org/10.1016/j.jtho.2019.10.024" @default.
- W2990621342 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31778797" @default.
- W2990621342 hasPublicationYear "2020" @default.
- W2990621342 type Work @default.
- W2990621342 sameAs 2990621342 @default.
- W2990621342 citedByCount "87" @default.
- W2990621342 countsByYear W29906213422020 @default.
- W2990621342 countsByYear W29906213422021 @default.
- W2990621342 countsByYear W29906213422022 @default.
- W2990621342 countsByYear W29906213422023 @default.
- W2990621342 crossrefType "journal-article" @default.
- W2990621342 hasAuthorship W2990621342A5002347804 @default.
- W2990621342 hasAuthorship W2990621342A5004505157 @default.
- W2990621342 hasAuthorship W2990621342A5008692926 @default.
- W2990621342 hasAuthorship W2990621342A5008781374 @default.
- W2990621342 hasAuthorship W2990621342A5009466654 @default.
- W2990621342 hasAuthorship W2990621342A5010884206 @default.
- W2990621342 hasAuthorship W2990621342A5022273534 @default.
- W2990621342 hasAuthorship W2990621342A5037468064 @default.
- W2990621342 hasAuthorship W2990621342A5039160380 @default.
- W2990621342 hasAuthorship W2990621342A5040095241 @default.
- W2990621342 hasAuthorship W2990621342A5041062966 @default.
- W2990621342 hasAuthorship W2990621342A5044755649 @default.
- W2990621342 hasAuthorship W2990621342A5048380048 @default.
- W2990621342 hasAuthorship W2990621342A5048517627 @default.
- W2990621342 hasAuthorship W2990621342A5055965589 @default.
- W2990621342 hasAuthorship W2990621342A5057281549 @default.
- W2990621342 hasAuthorship W2990621342A5065839430 @default.
- W2990621342 hasAuthorship W2990621342A5067755477 @default.
- W2990621342 hasAuthorship W2990621342A5070156025 @default.
- W2990621342 hasAuthorship W2990621342A5077579849 @default.
- W2990621342 hasAuthorship W2990621342A5077763767 @default.
- W2990621342 hasAuthorship W2990621342A5078248328 @default.
- W2990621342 hasAuthorship W2990621342A5086483620 @default.
- W2990621342 hasBestOaLocation W29906213421 @default.
- W2990621342 hasConcept C121608353 @default.
- W2990621342 hasConcept C126322002 @default.
- W2990621342 hasConcept C141071460 @default.
- W2990621342 hasConcept C143998085 @default.
- W2990621342 hasConcept C197934379 @default.
- W2990621342 hasConcept C2775949291 @default.
- W2990621342 hasConcept C2776256026 @default.
- W2990621342 hasConcept C2776694085 @default.
- W2990621342 hasConcept C2777701055 @default.
- W2990621342 hasConcept C2777714996 @default.
- W2990621342 hasConcept C2777742743 @default.
- W2990621342 hasConcept C2779524853 @default.